| Recruiting | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy NCT07309432 | Regeneron Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergi NCT06459219 | Sven Schneider, MD | — |
| Recruiting | Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis NCT07220408 | Telios Pharma, Inc. | Phase 2 |
| Completed | A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Part NCT06602739 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Par NCT06602726 | Regeneron Pharmaceuticals | Phase 3 |
| Recruiting | Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis NCT06686472 | Telios Pharma, Inc. | Phase 2 |
| Completed | A Study Of TL-925 For The Treatment of AC NCT06293820 | Telios Pharma, Inc. | Phase 2 |
| Unknown | A Study of TL-925 for the Treatment of Allergic Conjunctivitis NCT06153342 | Telios Pharma, Inc. | Phase 2 |
| Completed | A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults NCT05969236 | Shanghai Medinno Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dy NCT06800274 | Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | Phase 4 |
| Completed | Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combina NCT05815758 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | PMCF Study to Evaluate Performance and Safety of "Xanoftal Next" NCT05829499 | C.O.C. Farmaceutici S.r.l. | N/A |
| Completed | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis NCT05579730 | Bausch & Lomb Incorporated | Phase 3 |
| Enrolling By Invitation | The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visu NCT05839938 | China Medical University Hospital | N/A |
| Completed | PMCF Study to Evaluate Performance and Safety of "Optrex Double Action Soothing and Lubricating Drops" NCT05824000 | C.O.C. Farmaceutici S.r.l. | N/A |
| Completed | The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic NCT05234554 | Aldeyra Therapeutics, Inc. | Phase 3 |
| Completed | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subj NCT05314621 | Andover Research Eye Institute | Phase 4 |
| Completed | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Su NCT05265910 | Andover Research Eye Institute | Phase 4 |
| Unknown | Airway Immune Response to Allergens (Use Lay Language Here) NCT04619017 | JOSALYN CHO | Phase 1 |
| Completed | Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children NCT04810390 | Faes Farma, S.A. | Phase 3 |
| Completed | Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment NCT04776096 | Laboratorios Poen | Phase 4 |
| Unknown | Sea Water in Allergic Conjunctivitis NCT04695795 | University of Valencia | — |
| Completed | Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular NCT04622345 | Vanda Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Tyrosine Allergoid Paediatric and Adult Study NCT05186025 | Allergy Therapeutics | — |
| Completed | Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis NCT04532710 | Marinomed Biotech AG | Phase 2 |
| Completed | Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglob NCT04389034 | Allergy Therapeutics | — |
| Recruiting | Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface NCT04198740 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Withdrawn | Manuka Eye Droops for Treatment of Allergy NCT03862053 | Toyos Clinic | Phase 4 |
| Completed | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Co NCT04207736 | Aldeyra Therapeutics, Inc. | Phase 3 |
| Completed | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis NCT04050865 | Ocular Therapeutix, Inc. | Phase 3 |
| Unknown | Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest NCT03820154 | Prof. Dr. Claus Bachert BVBA | N/A |
| Completed | Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal S NCT03755557 | Marinomed Biotech AG | Phase 3 |
| Completed | Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study NCT03682965 | Christopher Thompson, MD | Phase 2 |
| Completed | A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjun NCT03660878 | Aldeyra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | China Red Eye Study on Allergic Conjunctivitis NCT03812952 | Sun Yat-sen University | — |
| Terminated | Molekule for Allergic Rhinitis/Asthma NCT03627689 | Molekule | N/A |
| Completed | A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthal NCT03489941 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. NCT03479307 | Faes Farma, S.A. | Phase 3 |
| Completed | ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis NCT03494504 | Aldeyra Therapeutics, Inc. | Phase 3 |
| Completed | Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivit NCT03368339 | Realm Therapeutics, Inc. | Phase 2 |
| Completed | Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjuncti NCT03320434 | ORA, Inc. | Phase 2 |
| Completed | A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model NCT03231969 | Faes Farma, S.A. | Phase 2 |
| Completed | Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC NCT04641130 | Alyatec | N/A |
| Terminated | Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections NCT03038971 | Woodmont Pharmaceuticals, Inc. | Phase 1 |
| Completed | Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis NCT02978183 | Noveome Biotherapeutics, formerly Stemnion | Phase 2 |
| Unknown | A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts NCT01012752 | Roxall Medizin | Phase 3 |
| Completed | Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers NCT03101618 | Gachon University Gil Medical Center | — |
| Completed | A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis NCT02578914 | Aldeyra Therapeutics, Inc. | Phase 2 |
| Completed | The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel NCT01686048 | Meir Medical Center | — |
| Completed | Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations NCT03861910 | Federico II University | — |
| Completed | A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Micro NCT02308501 | ORA, Inc. | Phase 4 |
| Completed | Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects NCT02322216 | Alcon Research | Phase 3 |
| Withdrawn | Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjuncti NCT01657240 | Laboratorios Sophia S.A de C.V. | Phase 3 |
| Completed | Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic NCT02148744 | Xencor, Inc. | Phase 1 |
| Completed | Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis NCT02079649 | Alcon Research | Phase 2 |
| Completed | A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) NCT02082899 | Eleven Biotherapeutics | Phase 2 |
| Completed | Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan NCT02251613 | Alcon Research | Phase 4 |
| Completed | A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle NCT01881113 | Aciex Therapeutics, Inc. | Phase 3 |
| Terminated | Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis NCT01860664 | Koffler Vision Group | Phase 2 |
| Unknown | The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions NCT01878929 | University Hospitals Cleveland Medical Center | Phase 1 / Phase 2 |
| Unknown | Ocular Allergy Treatment Practical Impact Trial NCT01808768 | Starx Research Center, LLC | Phase 4 |
| Completed | Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis NCT01743027 | Alcon Research | Phase 3 |
| Completed | A Six-Week Safety Study of an Investigational Ophthalmic Solution NCT01698814 | Alcon Research | Phase 3 |
| Completed | AGN-229666 for the Treatment of Allergic Conjunctivitis NCT01754766 | Allergan | Phase 2 |
| Completed | Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients NCT01697969 | Alcon Research | Phase 4 |
| Completed | A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle NCT01685242 | Aciex Therapeutics, Inc. | Phase 3 |
| Completed | Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes NCT01679015 | Schwartz Laser Eye Center | — |
| Completed | Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis NCT01639846 | C.T. Development America, Inc. | Phase 2 |
| Completed | An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conj NCT01561521 | Akorn, Inc. | Phase 3 |
| Completed | A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Co NCT01551056 | Aciex Therapeutics, Inc. | Phase 3 |
| Completed | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) NCT01534195 | ORA, Inc. | Phase 4 |
| Completed | Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunc NCT01479374 | Alcon Research | Phase 3 |
| Completed | Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis NCT01443442 | Southern California College of Optometry at Marshall B. Ketchum University | Phase 4 |
| Completed | An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Plac NCT01439815 | ORA, Inc. | Phase 4 |
| Unknown | Comparison of Tolerability Between Two Allergy Drops NCT01390961 | Hom, Milton M., OD, FAAO | Phase 4 |
| Completed | Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis NCT01320553 | Sun Pharma Advanced Research Company Limited | Phase 2 |
| Unknown | Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses NCT01337557 | Hom, Milton M., OD, FAAO | Phase 4 |
| Completed | A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With NCT01272089 | Alcon Research | Phase 4 |
| Completed | The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer NCT01346371 | Minnesota Eye Consultants, P.A. | Phase 4 |
| Completed | Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) M NCT01332188 | Aciex Therapeutics, Inc. | Phase 2 / Phase 3 |
| Completed | A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft NCT01339507 | Cunningham, Derek N., O.D., P.A. | — |
| Completed | Safety and Comfort of AL-4943A Ophthalmic Solution NCT01326858 | Alcon Research | Phase 1 |
| Completed | A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Dura NCT01275105 | Eye Therapies, LLC | Phase 2 |
| Completed | Assessment of Alcon's Ocular Image Quantification System NCT01282138 | Alcon Research | Phase 4 |
| Completed | Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen NCT01731249 | Stallergenes Greer | Phase 3 |
| Completed | Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms o NCT01203540 | Laboratoires Thea | Phase 4 |
| Completed | Patient Perception Study for AL-4943A NCT01294969 | Alcon Research | Phase 4 |
| Completed | Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers NCT01159015 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients NCT01174823 | Bausch & Lomb Incorporated | Phase 2 |
| Completed | Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Aller NCT01159769 | Alcon Research | Phase 4 |
| Completed | Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model NCT01134328 | Aciex Therapeutics, Inc. | Phase 2 |
| Completed | Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acet NCT01120132 | Fovea Pharmaceuticals SA | Phase 2 |
| Completed | Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge NCT01107405 | Bausch & Lomb Incorporated | Phase 2 |
| Completed | Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis NCT01119287 | Alcon Research | Phase 4 |
| Completed | Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients NCT01109485 | Alcon Research | Phase 4 |
| Completed | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conju NCT00770133 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctiviti NCT01037179 | Alcon Research | Phase 3 |
| Completed | AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation NCT01001091 | Alcon Research | Phase 2 |
| Completed | Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (C NCT00987272 | Alcon Research | Phase 3 |
| Completed | The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo NCT01471184 | Bitop AG | N/A |
| Withdrawn | To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen NCT00881673 | Alcon Research | Phase 2 |
| Completed | Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis NCT00882687 | Shire | Phase 2 |
| Completed | Safety and Efficacy Study of a Eye Drop for Eye Allergy NCT00889330 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers NCT00889252 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% O NCT00836485 | Senju USA, Inc. | Phase 2 |
| Completed | Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoin NCT00833495 | Fovea Pharmaceuticals SA | Phase 2 |
| Completed | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivi NCT00769886 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season NCT00982163 | ORA, Inc. | — |
| Completed | Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients W NCT00818805 | Alcon Research | Phase 4 |
| Completed | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) NCT00689078 | ORA, Inc. | Phase 4 |
| Completed | Olopatadine Eye Drops and Allergy Skin Testing NCT00775658 | Vanderbilt University Medical Center | N/A |
| Completed | Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomati NCT00574379 | Faes Farma, S.A. | Phase 2 |
| Completed | Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis NCT00586664 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis NCT00534794 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers NCT00569777 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers NCT00586625 | Bausch & Lomb Incorporated | Phase 3 |
| Withdrawn | Comparison of CL Wear Between Two Allergy Drops NCT00489398 | Hom, Milton M., OD, FAAO | Phase 4 |
| Completed | Montelukast as a Controller of Atopic Syndrome NCT00559546 | University of Helsinki | Phase 4 |
| Completed | Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Con NCT00445874 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis NCT00432757 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivi NCT00423007 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | Mast-Cell Stabilizing Effects of Olopatadine NCT00389025 | Alcon Research | Phase 4 |
| Completed | Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis NCT00364091 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis NCT00331500 | Alcon Research | Phase 3 |
| Completed | Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis NCT00244543 | Vistakon Pharmaceuticals | Phase 3 |
| Completed | Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis NCT00241319 | Vistakon Pharmaceuticals | Phase 3 |
| Terminated | Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan NCT00276445 | Meiji University of Oriental Medicine | Phase 4 |
| Completed | Effect of Olopatadine on Allergic Tear Mediators NCT00609128 | University of Wisconsin, Madison | N/A |
| Unknown | Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 NCT00298337 | University of Helsinki | Phase 2 / Phase 3 |
| Completed | A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis NCT01363713 | Santen Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis NCT01363700 | Santen Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study NCT00443105 | Assaf-Harofeh Medical Center | Phase 2 |
| Withdrawn | A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis NCT00375596 | Bausch & Lomb Incorporated | Phase 2 |